FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities

FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities

The FDA released eight new guidance documents between April and June 2026, including draft guidances on gene therapy genome editing and payor communications, plus final guidances on pregnancy safety studies and CMC flexibilities for cell and gene therapies. These updates signal the agency's evolving regulatory approach and create both opportunities and compliance requirements for pharmaceutical companies.

Key Takeaways

• FDA issued eight new guidance documents from April to June 2026, covering gene therapy, payor communications, CMC, pregnancy safety, CGM data, expanded access, and biomarker validation.
• Two draft guidances (payor communications and gene therapy prior knowledge) are open for public comment, signaling potential regulatory shifts.
• The CMC flexibilities guidance for cell and gene therapy products may reduce development timelines and costs for BLA submissions.
• BD teams and investors should assess how these guidances affect pipeline programs, particularly in gene editing and cell therapy.

The development

On June 3, 2026, the FDA updated its Recently Issued Guidance Documents page, listing eight new documents from the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). The new guidances include a draft titled Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers (June 2026, CDER/CBER); a draft titled Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing (June 2026, CBER); a final guidance on Postapproval Pregnancy Safety Studies (May 2026, CDER/CBER); a final guidance on Submitting Continuous Glucose Monitoring Data in Clinical Trials (May 2026, CDER/CBER); a final guidance on Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application (May 2026, CBER); a final guidance on Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers (April 2026, CDER/CBER/OCLiP/OCE); a draft guidance on Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing (April 2026, CBER); and a final guidance on Bioanalytical Method Validation for Biomarkers (CDER, date unspecified). The page, authored by CBER and published by the FDA, also provides links to a sortable list of all recently added guidance documents and a centralized search tool.

Implications for pharma teams

For BD teams and investors, the new guidances create both opportunities and compliance requirements. The CMC flexibilities guidance for cell and gene therapy products is particularly significant: it may enable faster and less costly BLA submissions by allowing more flexible manufacturing approaches, potentially accelerating time-to-market for developers. The draft guidance on leveraging prior knowledge in gene therapy genome editing could streamline development for companies with existing platform data, reducing redundant studies. Conversely, the draft on payor communications may impose new constraints on how manufacturers discuss products with payors and formulary committees, requiring careful legal review. The final guidance on pregnancy safety studies will affect postmarketing requirements for many products, while the expanded access Q&A document clarifies pathways for investigational drug access. Teams should also note the FDA's ongoing effort, initiated in late 2024, to improve guidance development and publication processes, which may lead to more frequent and predictable releases.

Frequently Asked Questions